Ritlecitinib is an orally available small molecule inhibitor of Janus kinase 3 (JAK3) that is used to treat severe alopecia areata. Ritlecitinib is associated with a low rate of transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury. It is grouped under the following drug class(es): Immunosuppressants and JAK inhibitors. Its therapeutic use is listed as anti-inflammatories and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ritlecitinibum, Litfulo and PF06651600. Its PubChem CID is 118115473.
Ritlecitinib
| CAS No | 1792180-81-4 |
|---|---|
| Molecular Formula | C15H19N5O |
| Molecular Weight | 285.34 g/mol |
| Synonyms | 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ritlecitinib is an orally available small molecule inhibitor of Janus kinase 3 (JAK3) that is used to treat severe alopecia areata.
The listed CAS number is 1792180-81-4.
The listed molecular formula is C15H19N5O.
The listed molecular weight is 285.34 g/mol.
1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one.
The source lists ritlecitinibum, Litfulo and PF06651600.